Plain-English translation of NCT05889247 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a simple blood test can better monitor your advanced lung cancer during immunotherapy treatment compared to standard CT scans. The blood test measures tiny pieces of cancer DNA circulating in your blood, which may detect changes in your cancer more accurately and quickly than imaging scans. Researchers want to see if this blood test can help doctors make better decisions about your treatment and possibly reduce the time you need to stay on medication.
Standard CT scans can be hard to interpret and don't always clearly show whether a treatment is working, especially with newer immunotherapy drugs that can cause confusing changes on scans. This blood test approach may provide clearer, faster answers about how your cancer is responding to treatment, helping doctors avoid giving ineffective treatments that cause unnecessary side effects.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups: one group will have their treatment monitored mainly by blood tests measuring cancer DNA, while the other group will have standard CT scan monitoring. In both groups, you will continue receiving immunotherapy and have quality of life assessments. The study will track how well each monitoring approach works and whether the blood test group can safely stop treatment earlier while maintaining good outcomes.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
Denmark